Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV
- 1 July 2012
- journal article
- correction
- Published by SAGE Publications in Antiviral Therapy
- Vol. 17 (5) , 869-881
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3Gastroenterology, 2010
- Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapyAlimentary Pharmacology & Therapeutics, 2010
- Rigid Interferon-α Subtype Responses of Human Plasmacytoid Dendritic CellsJournal of Interferon & Cytokine Research, 2008
- Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C†‡Hepatology, 2008
- Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis CNature Biotechnology, 2007
- Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseasesProceedings of the National Academy of Sciences, 2007
- Ligand-induced Assembling of the Type I Interferon Receptor on Supported Lipid BilayersJournal of Molecular Biology, 2004
- Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activitiesEuropean Journal of Immunology, 1999
- Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNα2 1 1Edited by A. R. FershtJournal of Molecular Biology, 1999
- Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cellsBiochemical and Biophysical Research Communications, 1983